Clinical Trials Browser

Head and Neck Neoplasms × tislelizumab × 30 days × Clear all

NCT05526924 2026-03-04

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms